Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Revenue Per Share for the year ending June 30, 2024

Kazia Therapeutics Limited Revenue Per Share is NA for the year ending June 30, 2024. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Kazia Therapeutics Limited Revenue Per Share for the year ending June 30, 2023 was USD 0.00, a 1,456.12% change year over year.
Kazia Therapeutics Limited Revenue Per Share for the year ending June 30, 2022 was USD 0.00, a -100.00% change year over year.
Kazia Therapeutics Limited Revenue Per Share for the year ending June 30, 2021 was USD 0.10, a 96,431.84% change year over year.
Kazia Therapeutics Limited Revenue Per Share for the year ending June 30, 2020 was USD 0.00, a -47.54% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years